Teva Goes After Mylan Over Copaxone Patents
The Israel-based drugmaker filed a complaint Tuesday in the U.S. District Court for the Southern District of New York, following Mylan's abbreviated new drug application with the U.S. Food and Drug Administration to introduce a generic version of Copaxone.
According to Teva, the latest of the patents-in-suit expires in February 2020. Copaxone, also known as latiramer acetate injection, is the No. 1 prescribed treatment...
To view the full article, register now.